⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ATHE News
Alterity Therapeutics Limited American Depositary Shares
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
globenewswire.com
ATHE
Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
globenewswire.com
ATHE
Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor
globenewswire.com
ATHE
Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
globenewswire.com
ATHE
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
globenewswire.com
ATHE
Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
globenewswire.com
ATHE